Collaboration Plan Sample Clauses

Collaboration Plan. The term “

Collaboration Plan. The Collaboration Plan as described in Schedule 18 (Technical Requirements) is specified in Appendix 11, as attached and forming part of this Schedule, and shall be amended or supplemented by the Contractor as required in accordance with Schedule 18 and in accordance with the procedure set out in Schedule 5 (Design and Plan Certification Process and Review Procedure).

Collaboration Plan. The initial Collaboration Plan is described in Exhibit D. The Steering Committee shall prepare an amended Collaboration Plan no later than [*] and every [*] thereafter, during the Contract Period. Such amended Collaboration Plans shall be appended to Exhibit D and made part of this Agreement.

Collaboration Plan. The research and preclinical Development activities of the Parties with respect to the Collaboration Program will be described in a “Collaboration Plan,” an initial version of which is attached hereto as Exhibit 2.1(b). The Collaboration Plan will include a budget for the remaining portion of the Calendar Year in which this Agreement is executed and the next succeeding Calendar Year, and a projected budget for the next Calendar Year thereafter or until the end of the Collaboration Program Term if shorter. The Collaboration Plan will be reviewed as necessary at each meeting of the JSC, and at any other time upon the request of either Party, and will be modified as appropriate at the direction of the JSC to reflect material scientific, commercial and other developments. In all events, the Collaboration Plan will be consistent and not conflict with the terms of this Agreement.

Collaboration Plan. (a) The Parties shall establish a research pre-clinical and clinical development plan for each Collaboration Product, as may be supplemented and amended from time to time by the Joint Steering Committee, as described in Section 2.2.2.(a) (each, a “Collaboration Plan”). The initial Collaboration Plan for the Initial Collaboration Products shall be attached hereto as Exhibit 3.1.2.(a).1, Exhibit 3.1.2.(a).2, Exhibit 3.1.2.(a).3 and Exhibit 3.1.2.(a).4. Subject to Servier’s exercise of the Servier Collaboration Option in accordance with Section 3.1.1.(c), the Parties shall within ninety (90) days of the exercise of the Servier Confidential

Collaboration Plan. The Parties will conduct each Program in accordance with the Collaboration Plan. Unless decided otherwise by the JRC, the Collaboration Plan will be updated annually by the JRC. The Collaboration Plan for the HB700 Program and, if Roche exercises the Option pursuant to Section 2.3.2, the *** Program will set forth: (a) the scope of the Program and the resources that will be dedicated to the activities contemplated within the scope of the Program, including the responsibilities of each Party; (b) specific objectives for each year, which objectives will be updated or amended, as appropriate, by the JRC as research progresses; (c) criteria for progression of Collaboration Compounds during the preclinical stages up to and including IND submission (“Selection Criteria”); (d) contents of the respective data packages that Parties shall provide to the JRC (“Data Packages”); and (e) budgets for the activities under the scope of the Program prior to Roche Go-Decision with respect to such Program, including a budget for the Trial Costs (“Collaboration Budget”). An initial Collaboration Budget for the HB700 Program and the *** Program, including the activities to be conducted pursuant to the Pre-Option *** Collaboration Plan is attached as Appendix 3.2.3(A). Prior to the Option Exercise, the *** Program will be conducted pursuant to the Pre-Option *** Collaboration Plan. The JRC shall review the Collaboration Plan on an ongoing basis and may amend such plan. Any such changes shall be reflected in written amendments to the Collaboration Plan. The initial Collaboration Plan, hereto attached as Appendix 3.2.3(B), relates to the HB700 Program and Initial Compounds (the “HB700 Collaboration Plan”) and includes a high-level plan for the First Human Trial for an Initial Compound, including clinical Endpoints, subject to further revisions. If Roche exercises the Option as set forth in Section 2.3.2, the Collaboration Plan shall be updated to include further development of the *** Program through a First Human Trial for an Option Compound, in the same manner as for the HB700 Program, with the Parties having the same responsibilities with respect to the *** Program as for the HB700 Program.

Collaboration Plan. The Parties will use Commercially Reasonable Efforts to conduct the Collaboration under the Collaboration Plan attached to the Agreement, as it may be amended in accordance with this Section 2.2 and Section 8. 1. Unless decided otherwise by the JRC, the Collaboration Plan sets forth (i) the scope of the Collaboration and the bandwidth that will be used to conduct the activities contemplated within the scope of the Collaboration, including the responsibilities of each Party and (ii) specific objectives, which objectives will be updated or amended, as appropriate, by the JRC as research progresses. The JRC shall review the Collaboration Plan on an ongoing basis and may update the Collaboration Plan. Any such updates shall be reflected in written amendments to the Collaboration Plan.

Collaboration Plan. At its initial meeting, the CMC shall develop the initial Collaboration Plan, which shall be provided to each of the Parties’ for review and approval within thirty (30) days of the initial meeting of the CMC. The Collaboration plan shall then govern the rights and obligations of the Parties’ with respect to the Project. The Collaboration Plan shall set forth, at minimum, the App Venture Technology and Cloud Star Technology to be submitted to the Project, the specific scope and goals of the Project, a general allocation of the responsibilities of the Parties and the timeline for carrying out such responsibilities, and the overall Project Term. The CMC may amend, modify, supplement or supersede the Collaboration Plain; provided, however, that the CMC may not alter the Collaboration Plan in any manner that prejudices the rights or increases the obligations of either Party without such Party’s consent or extends the Project Term for a total period greater than five (5) years from the Commencement Date.

Collaboration Plan. (a) In addition to such other responsibilities as may be agreed to by the parties from time to time, the Collaboration Committee shall develop, propose and oversee the implementation of an annual plan for the clinical development, marketing and promotion of the Product (the "Collaboration Plan"), including approval of each party's Promotional Budget for each Sales Year, a sampling program, sales targets, Product positioning, sales and marketing strategies, indications, and thought leader development. (b) The Collaboration Committee shall meet within thirty (30) days after the execution date hereof to develop a Collaboration Plan for the remainder of the first Sales Year. The Collaboration Committee shall finalize the Collaboration Plan for the second Sales Year by October 1, 1999. For each subsequent Sales Year, the Collaboration Plan for the subsequent Sales Year shall be finalized by October 1 of the current Sales Year. The parties agree that the Collaboration Plan for the ninth and tenth Sales Years shall be one and the same Collaboration Plan, which shall be finalized by October 1, 2006. Each Collaboration Plan, including the Promotional Budgets and clinical development expenses of each party, shall be subject to final review and acceptance by the Collaboration Committee, whose approval with regard to allocations set forth in such Promotional Budgets shall not be unreasonably withheld or delayed; provided, however, that each Collaboration Plan shall provide that neither party shall be required to expend Promotional Expenses exceeding the amounts set forth in Section 3.13, nor clinical development expenses exceeding the amounts set forth in Section 3.14. Any disputes between the parties concerning a Collaboration Plan which cannot be resolved by the Collaboration Committee shall be submitted by any representative of the Collaboration Committee to Xxxxxx'x Vice President, Pharmaceutical Commercial Operations, and to Cephalon's Chief Operating Officer for resolution. If such dispute cannot be resolved as aforesaid, the matter shall be submitted to alternative dispute resolution in accordance with Section 18.7 hereof. (c) The Collaboration Plan shall be reviewed by the Collaboration Committee at each quarterly meeting. Any changes to the Collaboration Plan proposed by the parties are subject to the prior approval of the Collaboration Committee.

Collaboration Plan. 2.1.1 During the term of this Agreement, the parties shall collaborate with each other in accordance with a written plan (the “Collaboration Plan”), to be adopted by the parties. The initial Collaboration Plan is attached hereto as Exhibit E and will include the following: (a) Intematix to use its best effort to optimize the performance of its phosphor with SemiLEDs’ LED dies having 390 – 470 mn wavelength, or such other wavelengths, as a pump source for both cold and warm light applications (“Phosphors”). (b) SemiLEDs to use its best effort to optimize the performance of its LED dies (“LED Chips”) using Phosphors. (c) Each of Intematix and SemiLEDs shall cooperate to develop the highest performing One Package Solution with the Products. (d) Each of Intematix and SemiLEDs shall ensure that each of their Products delivered under this Agreement are of the highest quality and performance. 2.1.2 The Collaboration Plan may be amended from time to time.